Semaglutide vs Tirzepatide in 2026: Head-to-Head Weight Loss Comparison
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-05-15 · 10 min read
Wegovy vs Zepbound: SURMOUNT-5 and STEP trials show meaningful differences in weight loss, side effects, and cardiovascular benefits. Here is the data.
The GLP-1 Showdown
Both semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) are GLP-1 agonists, but tirzepatide also activates GIP receptors — driving deeper weight loss.
SURMOUNT-5 Head-to-Head Results (72 weeks)
- Tirzepatide 15mg: -20.2% body weight
- Semaglutide 2.4mg: -13.7% body weight
- Tirzepatide advantage: 47% more weight lost
Side Effect Profile
Both cause nausea, vomiting, and constipation. Tirzepatide may be slightly better tolerated past week 12.
Sleep Apnea Connection
Tirzepatide reduced AHI by 55% in obese OSA patients in the SURMOUNT-OSA trial — many could discontinue CPAP therapy after sustained weight loss. Always retitrate with a sleep study before stopping CPAP.
For pricing and prescription guidance, see our GLP-1 medications guide.